Molecular Type 2 Diabetes Biomarker Identified
|
By LabMedica International staff writers Posted on 23 Feb 2016 |
|
Image: The HiScan SQ scanner (Photo courtesy of Illumina).
Type 2 diabetes mellitus (DM) is an established risk factor for a wide range of vascular diseases, including ischemic stroke (IS) as well as heart attacks, neuropathy and blindness.
Type 2 diabetes is a chronic illness characterized by the presence of elevated blood glucose levels and it accounts for between 80% and 90% of diabetes cases and is one of the major cardiovascular risk factors.
Scientists at the Hospital del Mar Medical Research Institute (Barcelona, Spain) investigated DNA methylation in the blood samples of a cohort of 355 stroke patients using a state-of-the-art technique that allows them to study more than 450,000 methylation points in the genome. In addition, the study compared the methylation profiles of diabetics and non-diabetics as well as their levels of glycosylated hemoglobin (HbA1c), a biomarker that indicates blood glucose levels over the past three months.
DNA samples were extracted from whole peripheral blood collected in 10 mL EDTA tubes. The Chemagic Magnetic Separation Module I system (Chemagen, Baesweiler, Germany) was used for DNA isolation in one cohort, and the Autopure LS (Qiagen, Hilden, Germany) in another. Genome-wide DNA methylation was assessed using the Illumina HumanMethylation450 Beadchip (Illumina Netherlands; Eindhoven, Netherlands) and the arrays were scanned with the Illumina HiScan SQ scanner.
The study was subsequently replicated in two cohorts from independent populations, with 167 and 645 patients respectively, confirming the relationship between Thioredoxin Interacting Protein (TXNIP) methylation, diabetes and glucose level dysfunction. Methylation of TXNIP was inversely and intensely associated with HbA1c levels specifically related to diabetic patients with poor control of glucose levels. The authors concluded that hypomethylation of the TXNIP gene is related to type 2 DM. The inverse relationship between TXNIP methylation and HbA1c values suggests that TXNIP hypomethylation is a consequence of sustained hyperglycemia levels.
Carolina Soriano-Tárraga, PhD, the lead author of the study said, “The methylation of this gene could be used as an early biomarker of dysfunction in the control of glucose levels. We are currently studying the implications and specific role of this gene in diabetes. In the future it could provide a possible therapeutic target for treating diabetes or controlling glucose concentrations.” The study was published originally online on December 7, 2015, in the journal Human Molecular Genetics.
Related Links:
Hospital del Mar Medical Research Institute
Chemagen
Illumina Netherlands
Type 2 diabetes is a chronic illness characterized by the presence of elevated blood glucose levels and it accounts for between 80% and 90% of diabetes cases and is one of the major cardiovascular risk factors.
Scientists at the Hospital del Mar Medical Research Institute (Barcelona, Spain) investigated DNA methylation in the blood samples of a cohort of 355 stroke patients using a state-of-the-art technique that allows them to study more than 450,000 methylation points in the genome. In addition, the study compared the methylation profiles of diabetics and non-diabetics as well as their levels of glycosylated hemoglobin (HbA1c), a biomarker that indicates blood glucose levels over the past three months.
DNA samples were extracted from whole peripheral blood collected in 10 mL EDTA tubes. The Chemagic Magnetic Separation Module I system (Chemagen, Baesweiler, Germany) was used for DNA isolation in one cohort, and the Autopure LS (Qiagen, Hilden, Germany) in another. Genome-wide DNA methylation was assessed using the Illumina HumanMethylation450 Beadchip (Illumina Netherlands; Eindhoven, Netherlands) and the arrays were scanned with the Illumina HiScan SQ scanner.
The study was subsequently replicated in two cohorts from independent populations, with 167 and 645 patients respectively, confirming the relationship between Thioredoxin Interacting Protein (TXNIP) methylation, diabetes and glucose level dysfunction. Methylation of TXNIP was inversely and intensely associated with HbA1c levels specifically related to diabetic patients with poor control of glucose levels. The authors concluded that hypomethylation of the TXNIP gene is related to type 2 DM. The inverse relationship between TXNIP methylation and HbA1c values suggests that TXNIP hypomethylation is a consequence of sustained hyperglycemia levels.
Carolina Soriano-Tárraga, PhD, the lead author of the study said, “The methylation of this gene could be used as an early biomarker of dysfunction in the control of glucose levels. We are currently studying the implications and specific role of this gene in diabetes. In the future it could provide a possible therapeutic target for treating diabetes or controlling glucose concentrations.” The study was published originally online on December 7, 2015, in the journal Human Molecular Genetics.
Related Links:
Hospital del Mar Medical Research Institute
Chemagen
Illumina Netherlands
Gold Member
Automatic Hematology Analyzer
CF9600
HPV Molecular Test
BD Onclarity HPV Assay
Automated Urinalysis Solution
UN-9000
Latest Clinical Chem. News
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
- Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
- Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
- New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
- Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
- Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
- Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
- ADLM Issues Laboratory Guidance for Gender-Diverse Patient Care
- FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
- Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
- Blood Test Detects More High-Risk Prostate Cancers Than PSA
- Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
- Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
Channels
Clinical Chemistry
view channel
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read more
Hematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
Immunology
view channel
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Microbiology
view channel
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
New Rapid Ebola Antigen Test Detects Infection at Point of Care
A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more
